Our approach
ARTIFICIAL INTELLIGENCE
AI has revolutionised the way drugs are discovered.We use AI to discover new indications for existing drugs, derisking clinical development and reducing the cost and time needed to bring an effective drug to market.
DRUG REPURPOSING
Our drug repurposing activities focus on orphan diseases with high unmet medical needs, high potential market values and high regulatory and IP protection. Drug repurposing significantly lowers drug development costs, decreases development time and represents a growing market, currently estimated at USD 317 billion..
ORPHAN DISEASES
Most orphan diseases are life threatening, therefore there is an urgent need to find new treatments. The global orphan disease market has been growing strongly at 10%+ CAGR and is expected to reach USD 242 billion in 2024.
SOMAI PRO, OUR AI ENGINE, IS A DIFFERENTIATED AND CLINICALLY VALIDATED PLATFORM
Based on genetic algorithms
It offers proven predictivity, reducing development time, risks and costs









Chemicalstructure

List of drugs for the indication
Identification of drugs for an indication








Drug

List of new indications for the drug
Identification of new indications for a drug
Identification of drugs for an indication
Chemicalstructure
List of drugs for the indication

Identification of new indications for a drug
List of new indications for the drug

Drug
Identification of drugs for an indication
Chemicalstructure
List of drugs for the indication

Identification of new indications for a drug
Drug
List of new indications for the drug

You can find articles about SOMAI-PRO published in Yahoo news, MarketWatch, Financial content. ONE NEWS SAN FRANCISCO.